$MIRM

3 stories mentioning MIRMUpdated 27d ago

Every FINWIRES story that references MIRM, newest first.

Mirum Pharmaceuticals Insider Sold Shares Worth $2,875,103, According to a Recent SEC Filing

Christopher Peetz, Director, Chief Executive Officer, on June 01, 2026, sold 30,000 shares in Mirum Pharmaceuticals (MIRM) for $2,875,103. Following the Form 4 filing with the SEC, Peetz has control over a total of 381,809 common shares of the company, with 194,309 shares held directly and 187,500 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1759425/000161474026000010/xslF345X05/form4-06022026_070609.xml

$MIRM

Research42d ago

Wolfe Research Initiates Mirum Pharmaceuticals With Outperform Rating

Mirum Pharmaceuticals (MIRM) has an average rating of Buy and mean price target of $146.58, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$MIRM

Wire54d ago

RBC Capital Adjusts Mirum Pharmaceuticals Price Target to $142 From $128, Maintains Outperform Rating

Mirum Pharmaceuticals (MIRM) has an average rating of Buy and mean price target of $146.36, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $103.03, Change: $-7.05, Percent Change: -6.40%

$MIRM

Track with the FINWIRES app suite

FolioX

Track MIRM in your portfolio

WheelAI

Analyze MIRM options with the wheel strategy

StockInsider

See market sentiment on MIRM